Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07147218 · ClinicalTrials.gov registry record · NA
Accelerated TMS for MDD
A NA study of Major Depressive Disorder, sponsored by Neuronetics.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 3
- Study locations
NCT07147218: Recruiting NA study of Major Depressive Disorder, sponsored by Neuronetics.
NCT07147218 is a NA study of Major Depressive Disorder that is actively recruiting participants, run by Neuronetics. The registered enrollment target is 50 participants, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (87% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07147218, a NA study of Major Depressive Disorder, is actively recruiting participants, sponsored by Neuronetics.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 3
- Study locations
Study Summary
An open-label, multi-center, prospective study to evaluate feasibility and efficacy of accelerated TMS for patients with Major Depressive Disorder (MDD).
Primary Outcome
Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-administered tool used to assess the severity of depressive symptoms. Scores range from 0 to 60, with higher scores indicating greater severity
Conditions Studied
Interventions
- DEVICE TMS
Study Locations (3)
New York
- Brighter Neurotherapeutics - New York
North Carolina
- TMS of the Carolinas - Charlotte
Washington
- New chapter TMS - Spokane
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2025-08-21 |
| Est. Completion | 2027-12-31 |
| Phase | NA |
What NCT07147218 shows while recruiting
NCT07147218 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 377-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (87% lower).
The record links to 1 condition, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which TMS is the first listed.
NCT07147218 reports a single indexed study location in New York, North Carolina, Washington.
Frequently Asked Questions
What is clinical trial NCT07147218 about?
NCT07147218 is a clinical study titled "Accelerated TMS for MDD". An open-label, multi-center, prospective study to evaluate feasibility and efficacy of accelerated TMS for patients with Major Depressive Disorder (MDD).
What is the current status of trial NCT07147218?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2025-08-21. Estimated completion is 2027-12-31.
What conditions does trial NCT07147218 study?
This clinical trial studies the following conditions: Major Depressive Disorder.
What interventions are being tested in trial NCT07147218?
The interventions under investigation include: TMS (DEVICE).
Who is sponsoring clinical trial NCT07147218?
This trial is sponsored by Neuronetics, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07147218 being conducted?
This trial has 3 study locations across New York, North Carolina, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07147218's enrollment target sits among peer trials
50 183rd of 282 higher than 97 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Taking Action for College Students
RECRUITING · NA
-
Targeting Large-scale Networks in Depression With Real-time Functional Magnetic Resonance Imaging (fMRI) Neurofeedback
RECRUITING · NA
-
Neural Correlates of Stress and Perceived Control in Adolescent Depression
RECRUITING · NA
-
Positive Processes and Transition to Health (PATH)
RECRUITING · NA
-
Getting Out of the House: Using Behavioral Activation to Increase Community Participation
RECRUITING · NA
-
Amygdala Neurofeedback for Depression - Large Scale Clinical Trial
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI